Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 57.23% | 37.81% | 53.24% | 20.35% | -43.15% |
| Total Depreciation and Amortization | 0.33% | 14.08% | 33.96% | 61.81% | 71.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 280.38% | 296.37% | 244.45% | 203.62% | -173.12% |
| Change in Net Operating Assets | -344.83% | -48.20% | -23.22% | 119.78% | 187.98% |
| Cash from Operations | 20.43% | 48.04% | 56.77% | 65.09% | -8.74% |
| Capital Expenditure | 18.36% | 81.07% | 79.45% | 90.35% | 90.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -100.00% | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -118.18% | -142.71% | -97.18% | 73.70% | -49.09% |
| Cash from Investing | -113.64% | -133.39% | -99.17% | 23.37% | -10.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.52% | 3,223.75% | 1,227.39% | 876.08% | 129.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -19.13% | 8,848.75% | 3,468.22% | 1,675.43% | 129.65% |
| Foreign Exchange rate Adjustments | 548.82% | -145.84% | -97.45% | -98.91% | 71.20% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -555.19% | -243.82% | 113.20% | 795.90% | -26.85% |